Don't build a wall between exploratory and canned analysis
scalingbiotech.substack.com
A couple weeks ago, I argued that supporting analysis within a biotech isn’t a monolithic problem - the specifics and the context vary by a number of parameters, and I discussed four of them. For most of these, you’re going to pick one option and stick with it, at least for each team in your organization. But there’s one dimension where you not only need to support the whole spectrum, but also a transition across the project’s lifetime: the level to which the analysis is exploratory vs canned.
Don't build a wall between exploratory and canned analysis
Don't build a wall between exploratory and…
Don't build a wall between exploratory and canned analysis
A couple weeks ago, I argued that supporting analysis within a biotech isn’t a monolithic problem - the specifics and the context vary by a number of parameters, and I discussed four of them. For most of these, you’re going to pick one option and stick with it, at least for each team in your organization. But there’s one dimension where you not only need to support the whole spectrum, but also a transition across the project’s lifetime: the level to which the analysis is exploratory vs canned.